Novartis AG

NVS | NYSE

Price Alert Chart Builder DCF Calculator

$141.38

+$0.40 (+0.28%)

Sep 22, 2026, 11:48 AM ET · Market open

Overview Rating Statistics Financials Earnings Analysts Ownership Dividends Profile

+0.28%

(1D)

Rating

Updated: Aug 10, 2026

67.3

Fundamentals Strong

Market Sentiment Neutral

Moat Narrow

Full Analysis

Why Price Moved

14 days ago

-13.93%

Novartis shares dropped due to a failed cholestero...

Key Statistics

Market Data

Market Cap $268.71B

1D Range

140 141.80

52W Range

121.57 170.46

Valuation (TTM)

PE 21.26

PB 6.45

EV/EBITDA 13.89

Valuation (NTM)

Forward PE 13.99

Forward PEG 1.85

Price Target $153

Cash Flow

FCF Yield 5.9%

SBC Adj. FCF Yield 5.7%

SBC Impact -3.6%

Margins

Gross Margin 74.3%

Operating Margin 30.5%

FCF Margin 28.4%

Growth (CAGR)

Revenue 3Y | 5Y 6.0% | 1.5%

Dil EPS 3Y | 5Y 22.7% | 10.9%

FCF 3Y | 5Y 7.1% | 8.9%

Returns

ROA 10.3%

ROE 29.6%

ROIC 13.4%

Financial Health

Net Debt

$39.66B

Current Ratio 0.86

Interest Coverage 11.88

Dividends

Div Yield 3.36%

Payout Ratio 71.5%

FCF Payout Ratio 57.0%

All Key Statistics

Loading financial charts...

Profile

Novartis AG is a holding company, which engages in the business of developing, manufacturing, and marketing healthcare products. Its product portfolio is heavily focused on innovative prescription med...

Sector Healthcare

Industry Drug Manufacturers - General

Employees 75,267

IPO Date Nov 6, 1996

Website www.novartis.com

Fiscal Year January - December

Full Company Profile

Latest News

1 day ago · zacks.com

NVS Gets Positive CHMP Opinion for Cosentyx for Another Indication

NVS' Cosentyx wins a positive EU opinion for PMR, backed by late-stage data, potentially expanding its use beyond existing inflammatory conditions.

6 days ago · reuters.com

Novartis halts ALS drug development after mid-stage trial failure

Novartis has halted development of an experimental drug for amyotrophic lateral sclerosis after it failed to meet goals ‌in a mid-stage study, marking the latest disappointment for the Swiss drugmaker this year.

7 days ago · reuters.com

Legend Biotech taps Novartis veteran Zhang as CEO

Legend Biotech on Tuesday appointed longtime Novartis executive Ingrid Zhang as its CEO, effective immediately, banking on an industry veteran to steer its expansion beyond blockbuster ‌cancer therapy Carvykti.

7 days ago · wsj.com

Legend Biotech is tapping a Novartis executive to run the cell-therapy maker, ending a nearly two-month search that began when former CEO Ying Huang resigned in July

Ingrid Zhang will take the helm of the cancer therapy company, filling a post vacant since its previous CEO abruptly resigned in July.

8 days ago · fool.com

Novartis Just Shook Up a Multibillion-Dollar Drug Race. What It Means for Eli Lilly Stock.

Novartis recently announced bad news for its Lp(a)-lowering drug, pelacarsen. Lilly is also developing a therapy for lowering Lp(a).

11 days ago · barrons.com

Novartis: More Pain on the Way?

The bad diagnoses just keep on coming for the Swiss drugmaker.

11 days ago · gurufocus.com

Novartis's $30 Billion Deal Spree Triggers a Boardroom Reckoning

Novartis (NVS), the global innovative-medicines company, confronted sharper questions over its dealmaking strategy Friday after clinical setbacks weakened confi

12 days ago · reuters.com

Focus: Novartis investors turn spotlight on M&A after trial setbacks

Novartis investors are set to step up scrutiny of the Swiss group's dealmaking strategy after setbacks to drugs it acquired through mergers and acquisitions hit its shares, raising concerns about its pipeline.

12 days ago · reuters.com

Major Novartis shareholder calls for board shake-up after drug trial setbacks

A major shareholder in Novartis has called for a shake-up of the Swiss drugmaker's board to improve corporate governance after its shares suffered a record fall this week following back-to-back trial setbacks.